Goldman Sachs’s Epizyme, Inc EPZM Stock Holding History

Goldman Sachs’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-36,200	Closed	-$581K	–	5615
2020 Q2	$581K	Hold	36,200	–	–	﹤0.01%	4290
2020 Q1	$561K	Buy	+36,200	New	+$777K	﹤0.01%	4146
2018 Q2	–	Sell	-40,000	Closed	-$710K	–	6134
2018 Q1	$710K	Buy	+40,000	New	+$676K	﹤0.01%	4265
2017 Q4	–	Sell	-49,700	Closed	-$947K	–	6764
2017 Q3	$947K	Buy	+49,700	New	+$758K	﹤0.01%	4618

Other funds holding EPZM

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Goldman Sachs's EPZM Position: Q3 2022 in Review

Goldman Sachs sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 2,629,998 shares — an estimated $3.87M sold.

Goldman Sachs first reported a position in EPZM in Q2 2014 and held it in 32 quarters. The position peaked at $11.9M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

Goldman Sachs reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
Goldman Sachs sold 2,629,998 Epizyme, Inc shares in Q3 2022, an estimated $3.87M.
Goldman Sachs first reported a position in Epizyme, Inc in Q2 2014 and held it in 32 quarters.
Goldman Sachs's Epizyme, Inc position peaked at $11.9M in Q4 2019.
0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.